January 13, 2010 - Changes in staffing in the emergency department impact the availability of diagnostic modalities or treatmentment options for care. As a result, stroke patients admitted to the hospital on the weekend are more likely to receive the clot-dissolving medication tissue plasminogen activator than patients admitted during the week, according to a study in the January issue of Archives of Neurology.

A combination of factors, including shortages in resources, expertise and providers, may lead to less aggressive and lower quality care on the weekends vs. weekdays.

According to the authors, Abby S. Kazley, Ph.D., and colleagues at Medical University of South Carolina, Charleston, differences in the aggressiveness of care may be explained by differences in access to equipment or clinicians, who might be busier with other patient care responsibilities during the week.

"Elective surgical procedures on weekends are rare, and this may contribute to decreased traffic and waiting time for diagnostic equipment, and result in quicker and more efficient diagnosis and determination of treatment," they wrote. "Reduced road traffic and job obligations on weekends may contribute to the possibility that patients with acute ischemic stroke arrive sooner at the hospital."

Although hospitals operate around the clock every day of the year, patients admitted on the weekends were 20 percent more likely to receive tissue plasminogen activator, which was administered to 229 weekend patients and 543 weekday patients. No statistically significant difference was observed in death rate between the two groups (3,993 patients admitted on weekdays died, compared with 1,420 admitted on weekends). The authors said the similarity in death rate indicates that patients who receive tissue plasminogen activator are more likely to die in the hospital than those who do not.

Despite the inconsistencies in care, the authors of the study found that stroke death rates appear similar among weekend and weekday admissions.

Reference: Arch Neurol. 2010;67(1):39-44).

For more information: www.jama.org


Related Content

News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 23, 2024 — Researchers at the National Institutes of Health (NIH) found that an artificial intelligence (AI) model ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 17, 2024 — Hyperfine, a groundbreaking medical device company that has redefined brain imaging with the world’s ...

Time July 17, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Clinical Trials

June 27, 2024 — Prenuvo, which makes whole-body MRI screening for early cancer detection and other diseases, has ...

Time June 27, 2024
arrow
News | Pediatric Imaging

June 25, 2024 — Rady Children’s Hospital-San Diego, one of the nation’s top pediatric health care systems, today ...

Time June 25, 2024
arrow
News | PET Imaging

June 18, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 18, 2024
arrow
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024
arrow
Subscribe Now